Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
TGen and Affymetrix Partner to Use GeneChip(R) DNA Analysis Products in Major
Collaborative Programs
Genotyping Technology that Leverages an Innovative Whole-Genome SNP Assay Is
Available to Commercial and Academic Research Partners and Future Collaborators
SANTA CLARA, Calif. and PHOENIX, Feb. 11 /PRNewswire-FirstCall/ -- Affymetrix,
Inc. , and the Translational Genomics Research Institute (TGen) announced today
that they have entered into a non-exclusive agreement under which TGen will
offer genotyping services to their collaborators and NIH funded core facility
programs using Affymetrix GeneChip(R) brand DNA analysis technology.
TGen currently runs gene expression core facility programs on the Affymetrix
platform for The National Institutes of Mental Health and the National
Institutes of Neurological Disease and Stroke. As part of this agreement, these
programs have been expanded to run the Affymetrix DNA analysis technologies.
Affymetrix and TGen also agreed to a framework under which they will collaborate
on future projects.
"Affymetrix Mapping 10K Array is a powerful tool for linkage analysis and is
available today," said Dietrich Stephan, Ph.D., Director of TGen's Neurogenomics
Program. "We recently completed a complete linkage study and reproduced the
disease causing gene in just five days using the 10K. Affymetrix' cutting edge
technology helped realize our vision of rapidly translating genomic discovery."
"TGen's geneticists, scientific team and one of the world's fastest super
computers dedicated to the study of genetics combined with the Affymetrix SNP
platform will help scientists accelerate research of complex diseases and we are
thrilled to be a part of that," said Affymetrix' Chief Commercial Officer Trevor
J. Nicholls, Ph.D. "The flexibility and affordability of the Mapping 10K will
allow TGen to provide both large research institutions and individual
researchers with the most powerful genotyping technology available today."
The Mapping 10K Array meets the growingcustomer demand for powerful SNP
genotyping solutions in basic research, clinical research and development, drug
discovery, and pharmacogenomics. The Mapping 10K Array brings whole genome SNP
analysis to the bench top by combining an innovative, scalable assay with a
proven information platform -- one primer, one array, 10,000 SNPs. The Mapping
10K delivers the most markers and highest resolution available in a single
experiment, making it easier to pinpoint genomic regions linked to disease.
Applications include genetic linkage studies of inherited disease in families,
cancer genetics, and population genetics.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip platform, to address growing markets
focused on understanding the relationship between genes and human health.
Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
About TGen:
The mission of the Translational Genomics Research Institute (TGen) is to make
and translate genomic discoveries into advances in human health. "Translational
genomics research" is a relatively new field employing innovative advances
arising from the Human Genome Project to apply to the development of
diagnostics, prognostics and therapiesfor cancer, neurologic disorders,
diabetes and other complex diseases.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, includingstatements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including, but
not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing, product
development, market acceptance (including uncertainties relating to product
development and market acceptance of the GeneChip 10K Mapping Array), personnel
retention, uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix' Form 10-K for the year ended December 31, 2002 and
other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Affymetrix' expectations with regard
thereto or any change in events, conditions, or circumstances on which any such
statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix, Inc.
CONTACT: media, Wes Conard, Associate Director, Public Relations,
+1-408-731-5791, or investors, Doug Farrell, Vice President, Investor
Relations, +1-408-731-5285, both of Affymetrix, Inc.
Web site: http://www.affymetrix.com/